WO1998022141A3 - Effets renforces pour therapeutique associee a l'haptene - Google Patents

Effets renforces pour therapeutique associee a l'haptene Download PDF

Info

Publication number
WO1998022141A3
WO1998022141A3 PCT/US1997/018475 US9718475W WO9822141A3 WO 1998022141 A3 WO1998022141 A3 WO 1998022141A3 US 9718475 W US9718475 W US 9718475W WO 9822141 A3 WO9822141 A3 WO 9822141A3
Authority
WO
WIPO (PCT)
Prior art keywords
enhanced effects
hapten conjugated
conjugate
half life
vivo half
Prior art date
Application number
PCT/US1997/018475
Other languages
English (en)
Other versions
WO1998022141A2 (fr
Inventor
Roland Buelow
Alexander R Lussow
Original Assignee
Sangstat Medical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sangstat Medical Corp filed Critical Sangstat Medical Corp
Priority to EP97949336A priority Critical patent/EP1027073A2/fr
Priority to AU72983/98A priority patent/AU7298398A/en
Publication of WO1998022141A2 publication Critical patent/WO1998022141A2/fr
Publication of WO1998022141A3 publication Critical patent/WO1998022141A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines

Abstract

L'invention a trait à de nouvelles méthodes permettant de renforcer la demi-vie efficace in vivo de composés thérapeutiques chez des mammifères. Plus particulièrement, ces composés thérapeutiques sont associés à une fraction haptène. A la suite de l'administration au mammifère, les conjugats - composé thérapeutique/haptène - sont fixés par des anticorps circulant dirigés de manière spécifique contre la fraction haptène du conjugat, ce qui se solde par une stabilisation du conjugat dans le système vasculaire et une augmentation réelle de la demi-vie in vivo du composé thérapeutique.
PCT/US1997/018475 1996-11-19 1997-11-06 Effets renforces pour therapeutique associee a l'haptene WO1998022141A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP97949336A EP1027073A2 (fr) 1996-11-19 1997-11-06 Effets renforces pour therapeutique associee a l'haptene
AU72983/98A AU7298398A (en) 1996-11-19 1997-11-06 Enhanced effects for hapten conjugated therapeutics

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75267196A 1996-11-19 1996-11-19
US08/752,671 1996-11-19

Publications (2)

Publication Number Publication Date
WO1998022141A2 WO1998022141A2 (fr) 1998-05-28
WO1998022141A3 true WO1998022141A3 (fr) 1999-01-07

Family

ID=25027301

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/018475 WO1998022141A2 (fr) 1996-11-19 1997-11-06 Effets renforces pour therapeutique associee a l'haptene

Country Status (3)

Country Link
EP (1) EP1027073A2 (fr)
AU (1) AU7298398A (fr)
WO (1) WO1998022141A2 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000022112A1 (fr) 1998-10-13 2000-04-20 The University Of Georgia Research Foundation, Inc. Peptides bioactifs stabilises, procedes d'identification, synthese et utilisation
US20030190740A1 (en) 1998-10-13 2003-10-09 The University Of Georgia Research Foundation, Inc Stabilized bioactive peptides and methods of identification, synthesis, and use
WO2001032207A1 (fr) * 1998-10-30 2001-05-10 United States Army Medical Research And Materiel Command Procede permettant d'appliquer une immunotherapie active/passive
JP2003518075A (ja) * 1999-12-24 2003-06-03 ジェネンテック・インコーポレーテッド 生理活性化合物の消失半減期延長のための方法及び組成物
EP1757311B1 (fr) * 1999-12-24 2009-02-11 Genentech, Inc. Méthodes et compositions pour la prolongation de la demi-période d'élimination de composés bioactifs
CN100560131C (zh) 2001-10-22 2009-11-18 斯克里普斯研究学院 抗体靶向化合物
EP1888640B1 (fr) 2005-05-18 2012-03-14 Ablynx N.V. Nanocorps ameliores utilises contre le facteur-alpha de necrose tumorale
WO2008074840A2 (fr) 2006-12-19 2008-06-26 Ablynx N.V. Séquences d'acides aminés dirigées contre une métalloprotéinase de la famille adam et polypeptides les comprenant à des fins de traitement de maladies et troubles liés à adam
EP2557090A3 (fr) 2006-12-19 2013-05-29 Ablynx N.V. Séquences d'acides aminés dirigées contre les GPCR et polypeptides les comprenant pour le traitement de maladies et de troubles liés au GPCR
WO2009124931A2 (fr) 2008-04-07 2009-10-15 Ablynx Nv Séquences d'acides aminés dirigées contre les voies notch et leurs utilisations
CA2731617A1 (fr) 2008-07-22 2010-01-28 Maria Joao Saraiva Sequences d'acides amines dirigees contre des recepteurs de desactiveurs multicibles et polypeptides
US8748581B2 (en) 2009-04-10 2014-06-10 Ablynx N.V. Anti-IL-6R polypeptides and pharmaceutical compositions thereof
SG176095A1 (en) 2009-06-05 2011-12-29 Ablynx Nv Monovalent, bivalent and trivalent anti human respiratory syncytial virus (hrsv) nanobody constructs for the prevention and/or treatment of respiratory tract infections
EP2507262A1 (fr) 2009-11-30 2012-10-10 Ablynx N.V. Séquences d'acides aminés améliorées dirigées contre le virus syncytial respiratoire humain (hrsv) et polypeptides comprenant celles-ci pour la prévention et/ou le traitement d'infections du tractus respiratoire
EP2513145B1 (fr) 2009-12-14 2018-01-24 Ablynx N.V. Domaines variables uniques de liaison anti-ox40l, construits et application therapeutique
WO2011083140A1 (fr) 2010-01-08 2011-07-14 Ablynx Nv Domaines variables simples d'immunoglobuline dirigés contre le cxcr4 doués d'une meilleure activité thérapeutique et produits de recombinaison les comprenant
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
EP3546483A1 (fr) 2010-05-20 2019-10-02 Ablynx N.V. Matériaux biologiques associés à her3
EP2638068B1 (fr) 2010-11-08 2018-12-26 Novartis AG Polypeptides se liant aux récepteurs de cxcr2
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
JP2014525736A (ja) 2011-06-23 2014-10-02 アブリンクス エン．ヴェー． ＩｇＥに対する免疫グロブリン単一可変ドメイン
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
WO2014087010A1 (fr) 2012-12-07 2014-06-12 Ablynx N.V. Polypeptides améliorés dirigés contre ige
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
WO2018014260A1 (fr) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Protéines de liaison antigènes multi-spécifiques et leurs procédés d'utilisation
WO2018068201A1 (fr) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Anticorps à domaine unique et ses variants contre ctla-4
CA3043515A1 (fr) 2016-11-16 2018-05-24 Ablynx Nv Polypeptides de recrutement de lymphocytes t capables de se lier a cd123 et tcr alpha/beta
EP3630818A1 (fr) 2017-06-02 2020-04-08 Ablynx NV Immunoglobulines liant l'aggrécane
CA3082280A1 (fr) 2017-12-28 2019-07-04 Nanjing Legend Biotech Co., Ltd. Anticorps a domaine unique et leurs variants diriges contre tigit
EP3740507A4 (fr) 2018-01-15 2022-08-24 Nanjing Legend Biotech Co., Ltd. Anticorps à domaine unique et des variants de celui-ci dirigés contre pd-1
WO2019185040A1 (fr) 2018-03-30 2019-10-03 Nanjing Legend Biotech Co., Ltd. Anticorps à domaine unique contre lag-3 et leurs utilisations
IL305301A (en) 2021-02-19 2023-10-01 Us Health Single domain antibodies neutralizing SARS CoV-2
WO2024083843A1 (fr) 2022-10-18 2024-04-25 Confo Therapeutics N.V. Séquences d'acides aminés dirigées contre le récepteur de la mélanocortine 4 et polypeptides les comprenant pour le traitement de maladies et de troubles liés à mc4r

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993017699A1 (fr) * 1992-03-02 1993-09-16 The Board Of Trustees Of The Leland Stanford Junior University Regulation de l'activite de lymphocytes a l'aide de peptides hla
DE4238416A1 (de) * 1992-11-13 1994-05-19 Max Planck Gesellschaft Bestimmung von Peptidmotiven auf MHC-Molekülen
WO1995034321A1 (fr) * 1994-06-16 1995-12-21 The Board Of Trustees Of The Leland Stanford Junior University Modulation immunitaire a l'aide de fragments de chaine alpha de classe ii
WO1996035443A1 (fr) * 1995-05-12 1996-11-14 Sangstat Medical Corporation Traitement destine a inhiber la progression de maladies auto-immunes
WO1997024140A1 (fr) * 1996-01-02 1997-07-10 The Board Of Trustees Of Leland Stanford Junior University Interaction de proteines hla avec des membres de la famille hsp70 de proteines
WO1997037690A2 (fr) * 1996-04-10 1997-10-16 Sangstat Medical Corporation Conjugues cytomodulants d'elements de paires de liaison specifiques

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993017699A1 (fr) * 1992-03-02 1993-09-16 The Board Of Trustees Of The Leland Stanford Junior University Regulation de l'activite de lymphocytes a l'aide de peptides hla
DE4238416A1 (de) * 1992-11-13 1994-05-19 Max Planck Gesellschaft Bestimmung von Peptidmotiven auf MHC-Molekülen
WO1995034321A1 (fr) * 1994-06-16 1995-12-21 The Board Of Trustees Of The Leland Stanford Junior University Modulation immunitaire a l'aide de fragments de chaine alpha de classe ii
WO1996035443A1 (fr) * 1995-05-12 1996-11-14 Sangstat Medical Corporation Traitement destine a inhiber la progression de maladies auto-immunes
WO1997024140A1 (fr) * 1996-01-02 1997-07-10 The Board Of Trustees Of Leland Stanford Junior University Interaction de proteines hla avec des membres de la famille hsp70 de proteines
WO1997037690A2 (fr) * 1996-04-10 1997-10-16 Sangstat Medical Corporation Conjugues cytomodulants d'elements de paires de liaison specifiques

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BUELOW R ET AL: "PROLONGATION OF SKIN ALLOGRAFT SURVIVAL IN MICE FOLLOWING ADMINISTRATION OF ALLOTRAP", TRANSPLANTATION, vol. 59, no. 4, 27 February 1995 (1995-02-27), pages 455 - 460, XP000652975 *
LUSSOW A R ET AL: "REDIRECTING CIRCULATING ANTIBODIES VIA LIGAND-HAPTEN CONJUGATES ELIMINATES TARGET CELLS IN VIVO", JOURNAL OF IMMUNOTHERAPY: WITH EMPHASIS ON TUMOR IMMUNOLOGY, vol. 19, no. 4, July 1996 (1996-07-01), pages 257 - 265, XP002050531 *

Also Published As

Publication number Publication date
AU7298398A (en) 1998-06-10
WO1998022141A2 (fr) 1998-05-28
EP1027073A2 (fr) 2000-08-16

Similar Documents

Publication Publication Date Title
WO1998022141A3 (fr) Effets renforces pour therapeutique associee a l'haptene
WO1997029779A3 (fr) Conjugues de egf-genisteine pour le traitement du cancer
ZA964614B (en) Methods for the preparation of substantially monomeric callcheamicin derivative carrier conjugates.
NO885199L (no) Fremgangsmaate for fremstilling av monoklonale antistoffkonjugater.
ID19188A (id) Metoda untuk menghasilkan asam linoleat konjugasi
EP0911036A3 (fr) Structure immunogene à double vecteur
EP1374908A3 (fr) Conjugués de polymère - médicament comprenant des groupes de liaison hydrazide
FI973002A (fi) Terapeuttinen yhdiste - rasvahappokonjugaatit
FR2696176B1 (fr) Dérivés de pipéridine, leur préparation et leur application en thérapeutique.
CA2150925A1 (fr) Synthese amelioree de conjugues polymeriques bioactifs
EP0630260A4 (fr) Conjugues de polysaccharide-proteine.
IL146015A0 (en) Methods for producing 5'-nucleic acid-protein conjugates
AU3076601A (en) Chemically-programmable immunity
TR199902775T2 (xx) 20(S)-Kamptotesin glikokonjugeleri.
MY134690A (en) Antitumor therapy comprising distamycin derivatives.
HUP0001069A3 (en) Method for producing an igm preparation for intravenous administration
CA2098593A1 (fr) Methode de traitement du cancer
DZ1718A1 (fr) Dérivés de pipéridine, leur préparation et leur application en thérapeutique.
CA2066031A1 (fr) Methodes de reduction de la retention non recherchee d'immunoconjugues et metabolites obtenus
AU3991899A (en) Verotoxin b subunit for immunization
WO2001040239A3 (fr) Conjugues metal de transition-cyclopentadienyle-tropane
CA2109572A1 (fr) Methode de reduction des effets secondaires de medicaments
FR2697520B1 (fr) Dérivés de benz[e]indende.
MX9704012A (es) Conjugados de interferon.
TR200102262T2 (tr) Koroner müdahale ile ilgili kardiovasküler olayların önlenmesi veya azaltılması için yöntem.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 1997949336

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWP Wipo information: published in national office

Ref document number: 1997949336

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1997949336

Country of ref document: EP